Literature DB >> 20609404

Targeting the undruggable proteome: the small molecules of my dreams.

Craig M Crews1.   

Abstract

Biologically active small molecules have long proven useful in the exploration of cell biology. Although many early compounds were by-products of drug development efforts, recent increased small molecule screening efforts in academia have expanded the repertoire of biological processes investigated to include areas of biology that are not of immediate pharmaceutical interest. Many of these new bioassays score for small molecule-induced phenotypic changes at the cellular or even organismal level and thus have been described as "chemical genetic" screens. However, this analogy with traditional genetic screens is misleading; although each gene has roughly an equivalent chance of being mutated in a traditional genetic screen, the amount of "proteomic space" that a chemical genetics approach can reach using current small molecule libraries is considerably smaller. Thus, new chemical biology methodologies are needed to target the remaining "undruggable proteome" with small druglike molecules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609404      PMCID: PMC2925121          DOI: 10.1016/j.chembiol.2010.05.011

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  46 in total

1.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.

Authors:  T U Mayer; T M Kapoor; S J Haggarty; R W King; S L Schreiber; T J Mitchison
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

Review 2.  The emerging power of chemical genetics.

Authors:  Kimberly M Specht; Kevan M Shokat
Journal:  Curr Opin Cell Biol       Date:  2002-04       Impact factor: 8.382

Review 3.  JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role.

Authors:  Kostas D Katsanakis; Carolyn Owen; Vassilis Zoumpourlis
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

4.  Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor.

Authors:  Aaron F Straight; Amy Cheung; John Limouze; Irene Chen; Nick J Westwood; James R Sellers; Timothy J Mitchison
Journal:  Science       Date:  2003-03-14       Impact factor: 47.728

5.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

Authors:  Yukihiro Itoh; Minoru Ishikawa; Mikihiko Naito; Yuichi Hashimoto
Journal:  J Am Chem Soc       Date:  2010-04-28       Impact factor: 15.419

Review 6.  Histone deacetylase as a new target for cancer chemotherapy.

Authors:  M Yoshida; R Furumai; M Nishiyama; Y Komatsu; N Nishino; S Horinouchi
Journal:  Cancer Chemother Pharmacol       Date:  2001-08       Impact factor: 3.333

Review 7.  Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases.

Authors:  Michael S Saporito; Robert L Hudkins; Anna C Maroney
Journal:  Prog Med Chem       Date:  2002

8.  Chemical genetic control of protein levels: selective in vivo targeted degradation.

Authors:  John S Schneekloth; Fabiana N Fonseca; Michael Koldobskiy; Amit Mandal; Raymond Deshaies; Kathleen Sakamoto; Craig M Crews
Journal:  J Am Chem Soc       Date:  2004-03-31       Impact factor: 15.419

9.  Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.

Authors:  Kathleen M Sakamoto; Kyung B Kim; Rati Verma; Andy Ransick; Bernd Stein; Craig M Crews; Raymond J Deshaies
Journal:  Mol Cell Proteomics       Date:  2003-10-02       Impact factor: 5.911

10.  Eg5 is static in bipolar spindles relative to tubulin: evidence for a static spindle matrix.

Authors:  T M Kapoor; T J Mitchison
Journal:  J Cell Biol       Date:  2001-09-17       Impact factor: 10.539

View more
  36 in total

1.  Identification of hydrophobic tags for the degradation of stabilized proteins.

Authors:  Hyun Seop Tae; Thomas B Sundberg; Taavi K Neklesa; Devin J Noblin; Jeffrey L Gustafson; Anke G Roth; Kanak Raina; Craig M Crews
Journal:  Chembiochem       Date:  2012-01-23       Impact factor: 3.164

Review 2.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

3.  "Mallostery"-ligand-dependent protein misfolding enables physiological regulation by ERAD.

Authors:  Margaret A Wangeline; Randolph Y Hampton
Journal:  J Biol Chem       Date:  2018-07-17       Impact factor: 5.157

Review 4.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

5.  A HaloTag-based small molecule microarray screening methodology with increased sensitivity and multiplex capabilities.

Authors:  Devin J Noblin; Charlotte M Page; Hyun Seop Tae; Peter C Gareiss; John S Schneekloth; Craig M Crews
Journal:  ACS Chem Biol       Date:  2012-10-11       Impact factor: 5.100

6.  Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.

Authors:  Jeffrey L Gustafson; Taavi K Neklesa; Carly S Cox; Anke G Roth; Dennis L Buckley; Hyun Seop Tae; Thomas B Sundberg; D Blake Stagg; John Hines; Donald P McDonnell; John D Norris; Craig M Crews
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-17       Impact factor: 15.336

Review 7.  Induced pluripotent stem cells in cardiovascular drug discovery.

Authors:  Mark Mercola; Alexandre Colas; Erik Willems
Journal:  Circ Res       Date:  2013-02-01       Impact factor: 17.367

8.  Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface.

Authors:  Inge Van Molle; Andreas Thomann; Dennis L Buckley; Ernest C So; Steffen Lang; Craig M Crews; Alessio Ciulli
Journal:  Chem Biol       Date:  2012-10-26

9.  Biophysical screening for the discovery of small-molecule ligands.

Authors:  Alessio Ciulli
Journal:  Methods Mol Biol       Date:  2013

10.  MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.

Authors:  John Hines; Schan Lartigue; Hanqing Dong; Yimin Qian; Craig M Crews
Journal:  Cancer Res       Date:  2018-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.